Skip to content
Studies have shown that active fund managers routinely underperform the S&P500 index*
Home
Articles
WALL STREET X
Forecasts
Portfolios
Wall Street X
Articles
Forecasts
Portfolios
Search
Results for
{phrase}
(
{results_count}
of
{results_count_total}
)
Displaying
{results_count}
results of
{results_count_total}
BridgeBio Pharma, Inc. (NASDAQ: BBIO)
BBIO Stock Predictions and Ratings
WSX Rating:
STRONG BUY
WSX Forecast (1yr):
51.40%
Analyst Rating:
STRONG BUY
Analyst Forecast (1yr):
35.10%
BBIO Stock Analysis
BBIO
PE Ratio:
BBIO
PEG Ratio:
Not Available
BBIO
Forward EPS Growth (12 month):
0.00%
BBIO
PS Ratio:
22.1
BBIO
PSG Ratio:
0.3
BBIO
Forward Revenue Growth (12 month):
67.80%
BBIO Articles
No data was found